Evaluation of therapeutic effect in metastatic castration-resistant prostatic cancer using FDG-PET/CT
Not Applicable
- Conditions
- metastatic castration-resistant prostatic cancer
- Registration Number
- JPRN-UMIN000024237
- Lead Sponsor
- Dapartment of Diagnostic Radiology Kyoto University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Male
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients who have problems in communication. 2. Patients with deteriorated general condition. 3. Patients with severe hepatic/renal dysfunction. 4. Patients with uncontrollable diabetes mellitus. 5. Patients who received FDG-PET/CT within 3 weeks of informed consent. 6. Patients to whom physicians judged inappropriate for this study.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. FDG uptake parameters in metastatic lesions obtained before and 12 weeks after the start of treatment 2. Number of bone metastases detected by bone scintigraphy performed before and 12 weeks after the start of treatment 3. Size of metastatic lesion detected by X-ray CT performed before and 12 weeks after the start of treatment 4. Serum PSA levels before and 12 weeks after the start of treatment
- Secondary Outcome Measures
Name Time Method Prognostic information of mid-term follow-up patients